156 related articles for article (PubMed ID: 33999416)
21. Ectopic expression of recipient CD47 inhibits mouse macrophage-mediated immune rejection against human stem cell transplants.
Leung CS; Li J; Xu F; Wong ASL; Lui KO
FASEB J; 2019 Jan; 33(1):484-493. PubMed ID: 30004796
[TBL] [Abstract][Full Text] [Related]
22. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
23. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
24. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
25. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
26. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.
Iwamoto C; Takenaka K; Urata S; Yamauchi T; Shima T; Kuriyama T; Daitoku S; Saito Y; Miyamoto T; Iwasaki H; Kitabayashi I; Itoh K; Kishimoto J; Kohda D; Matozaki T; Akashi K
Exp Hematol; 2014 Mar; 42(3):163-171.e1. PubMed ID: 24269920
[TBL] [Abstract][Full Text] [Related]
27. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
[TBL] [Abstract][Full Text] [Related]
28. Human CD47 expression permits survival of porcine cells in immunodeficient mice that express SIRPα capable of binding to human CD47.
Wang C; Wang H; Ide K; Wang Y; Van Rooijen N; Ohdan H; Yang YG
Cell Transplant; 2011; 20(11-12):1915-20. PubMed ID: 21535911
[TBL] [Abstract][Full Text] [Related]
29. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
[TBL] [Abstract][Full Text] [Related]
30. A novel CD47-blocking peptide fused to pro-apoptotic KLA repeat inhibits lung cancer growth in mice.
Pan L; Hu L; Chen M; Song Y; Chen Z; Gu Y; Li C; Jiang Z
Cancer Immunol Immunother; 2023 Dec; 72(12):4179-4194. PubMed ID: 37831145
[TBL] [Abstract][Full Text] [Related]
31. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
[TBL] [Abstract][Full Text] [Related]
32. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
[TBL] [Abstract][Full Text] [Related]
33. CD47 is a Potential Target for the Treatment of Laryngeal Squamous Cell Carcinoma.
Yang C; Gao S; Zhang H; Xu L; Liu J; Wang M; Zhang S
Cell Physiol Biochem; 2016; 40(1-2):126-136. PubMed ID: 27855370
[TBL] [Abstract][Full Text] [Related]
34. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
[TBL] [Abstract][Full Text] [Related]
35. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
36. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
[TBL] [Abstract][Full Text] [Related]
37. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47.
Wang H; VerHalen J; Madariaga ML; Xiang S; Wang S; Lan P; Oldenborg PA; Sykes M; Yang YG
Blood; 2007 Jan; 109(2):836-42. PubMed ID: 17008545
[TBL] [Abstract][Full Text] [Related]
39. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
[TBL] [Abstract][Full Text] [Related]
40. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]